Exyte Acquires TTP Group to Boost Biopharma and Life Sciences Growth
Overview
Exyte has announced plans to acquire TTP Group, a well-known consulting and engineering firm for the pharmaceutical and chemical industries in Europe.
Exyte’s leadership believes that combining TTP’s engineering expertise with their project execution capabilities will solidify their position in Europe’s biotech and pharma markets.
TTP Services
TTP offers a broad range of services, from feasibility studies to construction management and validation services.
Exyte, TTP’s minority shareholders, and financial investor Robus Capital have signed a definitive agreement, with the purchase price remaining confidential.
The acquisition is subject to regulatory approval.
About TTP
TTP is a trusted partner for major biotech, pharma, and chemical companies in Europe, operating through its brands, Pharmaplan and Triplan.
The company provides end-to-end services, including engineering, procurement, construction management, and validation.
Exyte plans to integrate TTP’s operations into its own Biopharma and Life Sciences activities in Europe, creating a stronger partnership to serve the growing biotechnology and pharmaceutical industry across the continent.
TTP Projects
TTP undertakes a wide range of projects, from revamping existing plants to constructing new ones, and has a strategic presence across Europe with 27 locations in Austria, Belgium, France, Germany, and Switzerland.
In 2023, TTP’s workforce of around 1,000 employees generated sales of approximately €170 million.
The company aims to maintain its profitable growth trajectory in the years ahead.
About The Acquisition
The acquisition to enhance their ability to offer comprehensive services, from strategic planning to the construction of high-tech facilities.
TTP’s skilled workforce, including engineers, architects, and project managers, will contribute to Exyte’s future growth and success.
Companies Commitment
Both companies share a commitment to providing innovative and sustainable solutions for their clients, and they see the merger as a positive step toward continued growth in the booming pharmaceutical facilities market.
Increasing Investments
With increasing investments in pharmaceutical production facilities driven by population growth, aging demographics, and new technologies such as mRNA, the demand for new manufacturing capacities is set to rise.
Exyte and TTP will be well-positioned to meet these demands with flexible, digital, and sustainable solutions.
Exyte’s Biopharma and Life Sciences division is its second-largest segment by revenue, generating €580 million in 2023. Order intake rose by 12% to €650 million, and the company aims to grow this segment’s revenue beyond €1.5 billion in the medium term.
Exyte’s Latest Project
Recently, Exyte completed a groundbreaking project to build one of the fastest-ever greenfield drug substance facilities, taking less than 22 months from design to validation at an mRNA competence centre in Germany.